SOPHiA GENETICS to Highlight Innovations and Announcements

BOSTON & GENEVA, Switzerland, Sept. 20, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare software company, will TODAY host its first-ever Investor Day in-person at the PUBLIC hotel in New York City. The event will begin at 1:30 p.m. EDT and is expected to end around 5:30 p.m. EDT.

Moderators include:

  • Troy Cox, Chairman of the Board
  • dr Jurgi Camblong, Chief Executive Officer and Co-Founder
  • Ken Freedman, Chief Revenue Officer
  • Peter Casasanto, Chief BioPharma Officer
  • dr Philippe Menu, Medical Director
  • Abhi Verma, Chief Technology Officer
  • dr Zhenyu Xu, Chief Scientific Officer
  • Ross Muken, Chief Financial Officer

Today’s Investor Day offers investors the opportunity to hear from the company’s executive team about its key differentiators and strategies that will help drive the long-term growth of SOPHiA Genetics.

Due to limited capacities, advance registration is required for the face-to-face event. For more information, interested parties can contact Investor Relations at [email protected]

Also Read :  Lifestyle change lowers T2D risk in women with gestational diabetes mellitus history | Latest news for Doctors, Nurses and Pharmacists

In addition, the event will be webcast live and all interested parties are invited to access the webcast through the Investor Relations section of the Company’s website.

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life science research. It is the creator of the SOPHiA DDM™ platform, a cloud-native platform capable of analyzing data and extracting insights from complex multimodal datasets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services are currently used by a wide network of hospitals, laboratories and biopharmaceutical facilities worldwide. You can find more information on SOPHiAGENETICS.COM or on Twitter, LinkedIn, Facebook and Instagram. Where others see data, we see answers

SOPHiA GENETICS products are for research use only and are not intended for diagnostic procedures unless otherwise noted. The information in this press release relates to products that may or may not be available in various countries and may or may not have received regulatory approval or market clearance for various indications. Please contact [email protected] for the appropriate product information for your country of residence.

Also Read :  Study identifies common genetic variants associated with musical beat synchronization

Forward-Looking Statements by SOPHiA GENETICS:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact included in this press release, including statements about our future earnings and financial condition, business strategy, products and technology, and management’s plans and objectives for future operations, are forward-looking statements. Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors, including those described in our filings with the US Securities and Exchange Commission. There can be no assurance that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date of this release. We expressly disclaim any obligation or undertaking to update any of the forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. No representations or warranties (express or implied) are made as to the accuracy of such forward-looking statements.

Also Read :  4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD,

Investor contact:
Jennifer Pottage
Head of Investor Relations
[email protected]

Media contact:
Kelly Katapodis
Senior Manager, Media & Communications
[email protected]

Source link